Abcam, ab238924, Anti-PRKAR1A+PRKAR1B antibody [EPR8491] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal PRKAR1A antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR8491,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab238924 is the carrier-free version of
ab139695
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PRKAR1A and PRKAR1B also known as protein kinase A regulatory subunit 1 alpha and beta are key components of the cAMP-dependent protein kinase (PKA) complex. PRKAR1A has a mass of approximately 43 kDa while PRKAR1B mass closely resembles it. Both PRKAR1A and PRKAR1B are expressed in various tissues with PRKAR1A having a significant presence in heart and adrenal tissues and PRKAR1B more prominent in the brain. Their role involves regulating the location and activity of the catalytic subunits of PKA by binding cAMP which causes the release and activation of catalytic subunits.
Biological function summary
PRKAR1A and PRKAR1B participate in the regulation of PKA's activity which is important for cAMP signaling pathways. These proteins are part of the PKA holoenzyme complex functioning as inhibitory subunits. Upon binding cAMP they undergo a conformational change that releases PKA catalytic subunits allowing them to phosphorylate different substrates. This process affects cellular responses such as metabolism cell cycle progression and gene expression.
Pathways
The PKA signaling pathway is among the major pathways involving PRKAR1A and PRKAR1B. The pathway is linked to G protein-coupled receptors (GPCR) and the subsequent release of cAMP. Another important pathway is the MAPK/ERK pathway where PKA modulates the activity of certain MAPK-related proteins affecting cell division and differentiation. PRKAR1A and PRKAR1B are involved with other proteins like PRKACB and PRKACA which are catalytic subunits of PKA.
PRKAR1A mutations associate with Carney complex a disorder characterized by multiple neoplasms. This connection results from PRKAR1A gene inactivation that leads to dysregulation of cAMP signaling. PRKAR1B on the other hand relates to neuropsychiatric disorders like schizophrenia where altered PKA signaling affects neurotransmitter pathways. Both PRKAR1A and PRKAR1B's involvement with regulatory proteins like PP1 which interacts with PKA highlights their significance in disease pathogenesis.